Publikationer

2024

McCulloch DE, Liechti ME, Kuypers K, Nutt D, Lundberg J, Stenbæk DS, Butlen-Ducuing F, Haberkamp M, Thirstrup S, Knudsen GM. Knowledge Gaps in Psychedelic Medicalisation: Clinical Studies and Regulatory Aspects. Neuroscience Applied. 2024 Jan.

2023

Armand S, Madsen MK, Ozenne B, Preller K, Knudsen GM, Fisher PM, Stenbæk DS. Amygdala response to emotional faces following acute administration of psilocybin in healthy volunteers. Neuroscience Applied. 2023 Dec.

Hovmand OR, Jensen ME, Søgaard-Juul T, Madsen MK, Fisher PM, Stenbæk DS. Validation of the Danish translation of the revised mystical experience questionnaire (MEQ30) and possible impact of setting, dose and intention. Journal of Psychoactive Drugs. 2023 Dec.

Butlen-Ducuing F, McCulloch DE, Haberkamp M, Mattila T, Bałkowiec-Iskra E, Aislaitner G, Balabanov P, Lundberg J, Stenbæk DS, Elferink A, Knudsen GM, Thirstrup. The therapeutic potential of psychedelics: The European regulatory perspective. The Lancet. 2023 Feb.

Beckman M, Poulsen S, Doss M, Stenbæk DS. Editorial: The Psychotherapeutic Framing of Psychedelic Drug Administration. Frontiers Psychology. 2023 Jan.

2022

Burmester D, Madsen MK, Szabo A, Aripaka SS, Stenbæk DS, Frøkjær VG, Elfving B, Mikkelsen J, Knudsen GM, Fisher PM. Effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans. Comprehensive Psychoneuroendocrinology. 2022 Dec.

Olsen AS, Lykkebo-Valløe A, Ozenne B, Madsen MK, Stenbæk DS, Armand S, Mørup M, Ganz M, Knudsen GM, Fisher PM. Psilocybin modulation of dynamic functional connectivity associated with plasma psilocin and subjective effects. Neuroimage. 2022 Oct.

Messel C, Summer L, Bonde L, Beck BD, Stenbæk DS. Music programming for psilocybin-assisted therapy: guided imagery and music-informed perspectives. Frontiers Psychology. 2022 Oct.

Jensen ME, Stenbæk DS, Juul TS, Ekstrøm CT, Fisher P, Knudsen GM, Fink-Jensen. Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12 weeks clinical trial (The QUANTUM Trip Trial). BMJ Open. 2022 Sept.

Søndergaard A, Madsen, MK, Ozenne B, Armand S, McCulloch DE, Erritzoe D, Fisher PM, Knudsen GM, Stenbæk DS. Lasting increases in trait mindfulness after psilocybin correlates positively with mystical-type experience in healthy individuals. Frontiers Psychology. 2022 Sept.

McCulloch DE, Grzywacz MZ, Madsen, MK, Jensen PS, Ozenne B, Armand S, Knudsen GM, Fisher PM, Stenbæk DS. Psilocybin-induced mystical-type experiences are related to persisting positive effects: a quantitative and qualitative report. Frontiers Pharmacology. 2022 Feb.

2021

Madsen MK, Stenbæk DS, Arvidsson A, Armand S, Marstrand-Joergensen MR, Johansen SS, Linnet K, Ozenne B, Knudsen GM, Fisher PM. 2021. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. European Neuropsychopharmacology. 2021 June.

McCulloch DE, Madsen MK, Stenbæk DS, Kristiansen S, Ozenne B, Jensen PS, Knudsen GM, Fisher PM. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. Journal of Psychopharmacology. 2021 May.

2020

Stenbæk DS, Madsen, MK, Ozenne B, Kristiansen S, Burmester D, Erritzoe D, Knudsen GM, Fisher PM. Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. Journal of Psychopharmacology. 2020 Aug.

Madsen MK, Fisher PM, Stenbæk DS, Kristiansen S, Burmester D, Lehel S, Páleníček T, Svarer C, Ozenne B, Knudsen GM. A single dose of psilocybin is associated with long-term increased mindfulness, which is preceded by a proportional reduction in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology. 2020 Feb.

2018

Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzøe D, Ozenne B, Knudsen GM. Psychedelic experience correlates with cerebral serotonin 2A receptor occupancy and with plasma psilocin levels. Neuropharmacology. 2018 Dec.